BonesLabs Blog
Updates on our supply, methodology references, and notes from the bench — written by the BonesLabs team for the research community.
Showing 19-36 of 95 posts | page 2/6
Sermorelin: A GHRH(1–29) Analogue Used in Growth Hormone Research Research summary. Sermorelin is a synthetic peptide corresponding to the first 29 amino acid residues of human growth hormone-releasing hormone (GHRH), the bioactive N-terminal fragment that retains full receptor-activating activity. It was historically marketed in the United States as Geref for the diagnostic evaluation of pituitary […]
Semax: A Synthetic ACTH(4–10) Analogue Studied for Neuroprotection Research summary. Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia, structurally based on residues 4–10 of adrenocorticotropic hormone (ACTH) with a C-terminal Pro-Gly-Pro extension to extend stability. It is included on the Russian Vital and Essential Drugs list and has been […]
Semaglutide (Duplicate Entry) Note. This entry is a duplicate listing of Semaglutide that appeared a second time in the source catalogue. The full research write-up — covering molecular profile, GLP-1 receptor pharmacology, the SUSTAIN and STEP clinical-trial programmes, and the cardiovascular and weight-management indications — is consolidated under the primary Semaglutide entry. Please refer to […]
Selank: A Synthetic Tuftsin Analogue Studied for Anxiolytic Activity Research summary. Selank is a synthetic heptapeptide developed at the Russian Institute of Molecular Genetics, structurally derived from the immunomodulatory tetrapeptide tuftsin with an added Pro-Gly-Pro tripeptide sequence to extend metabolic stability. The added C-terminal sequence prolongs plasma half-life from minutes to hours, enabling intranasal administration […]
Retatrutide (LY3437943): A Triple GLP-1 / GIP / Glucagon Receptor Agonist Research summary. Retatrutide is a once-weekly synthetic peptide developed by Eli Lilly that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors. It represents the next evolutionary step beyond GLP-1 monoagonists (semaglutide, liraglutide) and the GLP-1/GIP dual agonist tirzepatide, adding glucagon-receptor […]
PT-141 (Bremelanotide): A Melanocortin Receptor Agonist Approved for HSDD Research summary. PT-141, also known by its INN bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from the alpha-melanocyte-stimulating hormone (α-MSH) lineage. It binds preferentially to MC4R with additional activity at MC1R. Bremelanotide was approved by the FDA in 2019 under the trade name […]
Prostamax: A Khavinson Tetrapeptide Bioregulator Studied in Prostate Tissue Models Research summary. Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro / KEDP) belonging to the Khavinson "peptide bioregulator" family. The published literature describes effects on heterochromatin condensation, lymphocyte function, and prostate-tissue inflammation endpoints in rodent models. As with the rest of the Khavinson tripeptide and tetrapeptide series, […]
PNC-27: A Membranolytic Anti-Cancer Peptide Targeting HDM-2 Research summary. PNC-27 is a synthetic chimeric peptide consisting of an HDM-2 binding domain (corresponding to residues 12–26 of the p53 tumour-suppressor protein) fused to a membrane-penetrating sequence. It was developed at SUNY Downstate Medical Center by Pincus and Michl, originally in the context of HIV research, and […]
Pinealon: A Khavinson Tripeptide Bioregulator Studied for Neuroprotection Research summary. Pinealon is a synthetic tripeptide (Glu-Asp-Arg) belonging to the Khavinson "peptide bioregulator" family developed at the St. Petersburg Institute of Bioregulation and Gerontology. The proposed mechanism — direct interaction with chromatin and gene-expression modulation rather than canonical receptor binding — is unusual relative to most […]
PEG-MGF (Pegylated Mechano-Growth Factor): A Half-Life-Extended IGF-1Ec C-Terminal Peptide Research summary. PEG-MGF is a polyethylene-glycol (PEG)-conjugated form of MGF (Mechano-Growth Factor), the synthetic peptide corresponding to the unique C-terminal E-domain of the IGF-1Ec splice variant. PEGylation is added to address the very short plasma half-life of unmodified MGF E-domain peptide, extending in vivo exposure and […]
PE-22-28: A Spadin-Derived TREK-1 Channel Blocker in Antidepressant Research Research summary. PE-22-28 is a synthetic short peptide derivative of spadin, an endogenous peptide produced from cleavage of the sortilin (NTSR3) propeptide. Both spadin and PE-22-28 act as inhibitors of the TREK-1 (TWIK-related potassium channel-1) two-pore-domain potassium channel, which is highly expressed in CNS regions implicated […]
Pancragen (KEDW Tetrapeptide): A Khavinson Bioregulator with Reported Pancreatic Tropism Research summary. Pancragen is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Trp, KEDW) developed within the Khavinson short-peptide bioregulator programme, with reported tissue tropism for the pancreas. It sits within the broader Khavinson family of tissue-tropic short peptides (Cardiogen, Bronchogen, Cortagen, Ovagen, Pinealon, Vesugen, Prostamax) and shares the […]
P21 (P021): An Adamantylated Peptidomimetic Derived from Ciliary Neurotrophic Factor Research summary. P21 (also written P021) is a small synthetic peptidomimetic derived from the most active region of ciliary neurotrophic factor (CNTF). It consists of a tetrapeptide based on residues 148–151 of CNTF (Asp-Gly-Gly-Leu) modified with an adamantylated glycine intended to enhance proteolytic stability and […]
Oxytocin: A Nine-Residue Posterior-Pituitary Neuropeptide with Dual Hormone and Neuropeptide Roles Research summary. Oxytocin is a nine-residue cyclic peptide hormone synthesised primarily by magnocellular neurons of the hypothalamic paraventricular and supraoptic nuclei and released into systemic circulation by the posterior pituitary. It also functions as a CNS neuropeptide acting locally within the brain. Oxytocin has […]
Ovagen (EDL Tripeptide): A Khavinson Bioregulator with Reported Hepatic and GI-Mucosal Activity Research summary. Ovagen is a synthetic tripeptide bioregulator (Glu-Asp-Leu, EDL) developed within the Khavinson short-peptide bioregulator programme, with reported tissue tropism for the liver and gastrointestinal tract. It is not to be confused with another product marketed under a similar name containing ovine […]
Orforglipron: An Oral Non-Peptide Small-Molecule GLP-1 Receptor Agonist Research summary. Orforglipron is an investigational oral, non-peptide, small-molecule GLP-1 receptor agonist being developed by Eli Lilly. It represents one of the most clinically advanced examples of a strategic shift in the GLP-1-class incretin landscape: replacing parenteral peptide-based GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) with orally bioavailable […]
Orexin-A (Hypocretin-1): A Hypothalamic Neuropeptide in Wakefulness and Sleep-State Research Research summary. Orexin-A (also known as hypocretin-1) is a 33-residue hypothalamic neuropeptide produced from the prepro-orexin precursor, which also gives rise to orexin-B (hypocretin-2). The orexin system is one of the dominant systems for stabilising wakefulness and inhibiting inappropriate transitions into rapid eye movement (REM) […]
Noopept (GVS-111, N-Phenylacetyl-L-Prolylglycine Ethyl Ester): A Dipeptide Cognition-Research Compound Research summary. Noopept (development code GVS-111; chemical name N-phenylacetyl-L-prolylglycine ethyl ester) is a small dipeptide-derived research compound originally developed in Russia as a structural analogue and pharmacological successor to the racetam-class nootropic piracetam. It is a dipeptide ester of phenylacetic acid linked to L-proline-glycine, and is […]